Therefore, we conducted the first systematic review and meta-analysis to the best of our knowledge, evaluating the association between visfatin and NAFLD, the presence and severity of hepatic steatosis, liver fibrosis, lobar inflammation, and NASH, in addition to possible gender differences. This evidence concerns the gene NAMPT and metabolic dysfunction-associated steatohepatitis.